Free Trial
NASDAQ:BIOL

BIOLASE (BIOL) Stock Price, News & Analysis

BIOLASE logo

About BIOLASE Stock (NASDAQ:BIOL)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.0010
$0.0125
52-Week Range
N/A
Volume
N/A
Average Volume
2.58 million shs
Market Capitalization
$581 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$0.40
Consensus Rating
Buy

Company Overview

BIOLASE Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
25th Percentile Overall Score

BIOL MarketRank™: 

BIOLASE scored higher than 25% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BIOLASE has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Upside Potential

    BIOLASE has a consensus price target of $0.40, representing about ∞ upside from its current price of $0.00.

  • Amount of Analyst Coverage

    BIOLASE has received no research coverage in the past 90 days.

  • Read more about BIOLASE's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BIOLASE is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BIOLASE is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Short Interest

    There is no current short interest data available for BIOL.
  • Dividend Yield

    BIOLASE does not currently pay a dividend.

  • Dividend Growth

    BIOLASE does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for BIOL.
  • News Sentiment

    BIOLASE has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.94 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for BIOLASE this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, BIOLASE insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.27% of the stock of BIOLASE is held by insiders.

  • Percentage Held by Institutions

    Only 8.79% of the stock of BIOLASE is held by institutions.

  • Read more about BIOLASE's insider trading history.
Receive BIOL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOLASE and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BIOL Stock News Headlines

Forget AI Stocks — This Device Will REPLACE the Microchip
While everyone's chasing the same AI plays, George Gilder is focused on something completely different. He says a 4-nanometer device that's 80 MILLION times more powerful than the chip he gave Reagan is now being made in America for the first time. And he's identified 3 companies that control this technology.tc pixel
Biolase Inc (BIOLQ)
Biolase Inc. Faces Bankruptcy Amid Strategic Asset Sale
Sonendo, Inc. Reports Third Quarter 2024 Financial Results
See More Headlines

BIOL Stock Analysis - Frequently Asked Questions

BIOLASE, Inc. (NASDAQ:BIOL) released its earnings results on Wednesday, November, 10th. The medical technology company reported ($50.00) EPS for the quarter, beating the consensus estimate of ($75.00) by $25.00. The medical technology company had revenue of $9.53 million for the quarter. BIOLASE had a negative net margin of 41.65% and a negative trailing twelve-month return on equity of 1,782.73%.

BIOLASE's stock reverse split before market open on Friday, July 28th 2023.The 1-100 reverse split was announced on Friday, July 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Shares of BIOL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BIOLASE investors own include Bionano Genomics (BNGO), Tonix Pharmaceuticals (TNXP), SNDL (SNDL), Zomedica (ZOM), NIO (NIO), Exela Technologies (XELA) and Ocugen (OCGN).

Company Calendar

Last Earnings
11/10/2021
Today
9/15/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Dental equipment & supplies
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:BIOL
Previous Symbol
NASDAQ:BLTI
CIK
811240
Employees
160
Year Founded
1987

Price Target and Rating

High Price Target
$0.40
Low Price Target
$0.40
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($14.94)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$20.63 million
Net Margins
-41.65%
Pretax Margin
-41.56%
Return on Equity
-1,782.73%
Return on Assets
-55.31%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.71
Quick Ratio
0.36

Sales & Book Value

Annual Sales
$48.83 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.07) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
33,407,000
Free Float
33,317,000
Market Cap
$581 thousand
Optionable
Not Optionable
Beta
0.67

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:BIOL) was last updated on 9/15/2025 by MarketBeat.com Staff
From Our Partners